-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Furosemide Injection Has Passed the Consistency Evaluation
Category:
发布时间：2024-12-28
【概要描述】
Recently, Shijiazhuang Sihua Pharmaceutical Group received the “Notice of Approval for Supplementary Drug Application” issued by the National Medical Products Administration for Furosemide Injection (2 mL: 20 mg), signifying that this product has passed the evaluation of quality and therapeutic equivalence for generic drugs. To date, the company has cumulatively achieved such evaluation for 111 drug varieties encompassing 146 dosage forms and specifications.
Recently, Shijiazhuang Sihua Pharmaceutical Group received the “Notice of Approval for Supplementary Drug Application” issued by the National Medical Products Administration for Furosemide Injection (2 mL: 20 mg), signifying that this product has passed the evaluation of generic drug quality and therapeutic equivalence. To date, the company has cumulatively obtained approval for 146 specifications across 111 drug varieties.
According to available information, furosemide injection is a commonly used diuretic and is listed in the National Essential Medicines List as well as in the Class A category of the National Medical Insurance Catalogue. It is primarily indicated for the treatment of various edematous conditions, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), acute drug and toxin poisoning (such as barbiturate poisoning), and the prevention of acute renal failure.
Currently, furosemide is available in the domestic market primarily in three dosage forms: furosemide injection, furosemide tablets, and injectable furosemide (sterile powder for injection). According to data from MeneNet, sales of furosemide injection have generally shown a steady upward trend in recent years. In 2021, total sales across the three major distribution channels—urban public hospitals, county-level public hospitals, and township health centers—amounted to RMB 379 million; in 2022, sales reached RMB 497 million; in 2023, they stood at RMB 496 million; and in the first half of 2024, sales totaled RMB 198 million, indicating that there is still room for further growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091